法洛四联症修复术后室性心动过速的外科消融
本研究评估法洛四联症修复术后患者因肺动脉瓣反流行再次手术时,同期行外科射频消融室性心动过速的安全性和有效性。20例电生理检查阳性患者接受肺动脉瓣置换及术中消融,中位随访6.5年,1年和5年无室性心律失常生存率分别为94%和89.5%,无操作相关并发症。
要点
- 法洛四联症修复术后肺动脉瓣反流患者再次手术时,可同期行外科射频消融室速。
- 术前电生理检查阳性并识别缓慢传导峡部是消融靶点选择的关键。
- 术后电生理检查仍可诱发室速者建议植入ICD作为一级预防。
核心结论
- 肺动脉瓣置换同期行术中室性射频消融可预防早中期室性心律失常发生,可作为选定患者的安全附加手术。
研究设计与样本
- 单中心回顾性队列研究,2002年1月至2016年2月共118例法洛四联症修复术后因肺动脉瓣反流行再次手术,其中20例有室性心律失常危险因素且电生理检查阳性者接受肺动脉瓣置换及同期外科射频消融。
主要发现
- 20例患者均完成肺动脉瓣置换和外科心室射频消融,1例死于V-V ECMO期间呼吸衰竭,无晚期死亡。
- 中位随访6.5年,术后电生理检查15.7%患者仍可诱发室速并植入ICD,其余患者不再诱发。
- 无操作相关并发症,1年和5年无室性心律失常生存率分别为94%和89.5%。
关键数值与推荐
- 电生理检查阳性患者平均QRS时限178 ms,所有患者存在右心室功能障碍,20%合并三尖瓣反流。
临床怎么用
- 对法洛四联症修复术后因肺动脉瓣反流需再次手术且存在室性心律失常危险因素者,可考虑术前电生理检查并在术中同期消融缓慢传导峡部。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Life expectancy of patients with repaired tetralogy of Fallot is normal until adulthood, when it becomes burdened by major complications such as cardiac arrhythmias and heart failure. Ventricular tachycardia (VT), associated with electrical conduction abnormalities in anatomical isthmuses, is the most common complication and is refractory to medical therapy. The arrhythmogenic sources can be surgically ablated during reoperations for pulmonary valve incompetence. The purpose of our study is to evaluate the safety and effectiveness of surgical radiofrequency ablation during PVR and its long-term impact on the occurrence of cardiac events. METHODS: A total of 118 patients with repaired tetralogy of Fallot underwent reoperation for pulmonary valve regurgitation in IRCCS-Policlinico San Donato between January 2002 and February 2016. Twenty patients with risk factors for ventricular arrhythmia underwent EP testing and were found positive. The mean QRS duration was 178 ms. Right ventricular dysfunction was present in all the patients, and 20% had associated tricuspid regurgitation. The cohort (N = 20), with positive EP study, underwent pulmonary valve replacement and concomitant intraoperative ventricular surgical radiofrequency ablation, targeting the slow conducting isthmuses identified during preoperative electroanatomical mapping. All patients were reviewed at 1 month, 3 months and 6 months with clinical evaluation, echocardiography, ECG and implantable cardioverter-defibrillator interrogation. At 6 months, a postoperative electrophysiological study was performed in all patients, and a cardioverter defibrillator was implanted as primary preventive measure in patients with residual inducible VT. RESULTS: Pulmonary valve replacement and surgical ventricular radiofrequency ablation were performed in all cases. One patient died while on V-V extracorporeal membrane oxygenation (ECMO) due to respiratory failure. There was no late mortality. Follow-up was complete with a median of 6.5 years. During the postoperative EPS study, inducible VT was found in 15.7% of patients who received an implantable cardioverter-defibrillator, whereas VT could no longer be induced in the remaining patients. No procedure-related complication was observed, and freedom from ventricular arrhythmia was 94% and 89.5% at 1 year and 5 years, respectively. CONCLUSIONS: Pulmonary regurgitation and right ventricular dysfunction correlate with VT and SCD, but valve replacement alone does not reduce the risk of ventricular tachyarrhythmias. Intraoperative ventricular ablation during reoperation for pulmonary regurgitation prevents the occurrence of ventricular arrhythmias in the early and medium term. Accordingly, this technique may be proposed as a safe associated procedure in selected patients.
引用
- Caldaroni F, Lo Rito M, Chessa M, et al. Surgical ablation of ventricular tachycardia in patients with repaired tetralogy of Fallot†. Eur J Cardiothorac Surg. 2019. PMID: 30590464. doi:10.1093/ejcts/ezy407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。